The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling

被引：9

作者：

Verret, Benjamin ^{[1
,2
]}

Bottosso, Michele ^{[2
,3
]}

Hervais, Sofia ^{[2
]}

Pistilli, Barbara ^{[1
]}

机构：

[1] Gustave Roussy Canc Campus, Med Oncol Dept, F-94800 Villejuif, France

[2] Gustave Roussy Canc Campus, Unit U981, INSERM, F-94805 Villejuif, France

[3] Univ Padua, Dept Surg Oncol & Gastroenterol, I-35122 Padua, Italy

来源：

CANCERS | 2022年 / 14卷 / 17期

关键词：

metastatic breast cancer; molecular profilig; molecular biology; targeted therapy; precision medicine; biomarker; GENE-EXPRESSION PROFILES; EVEROLIMUS EFFICACY; DOUBLE-BLIND; PHASE-II; CHEMOTHERAPY; MUTATIONS; OUTCOMES; GROWTH; CLASSIFICATION; TRASTUZUMAB;

D O I：

10.3390/cancers14174203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary We propose in this article to review the state of knowledge about predictive and prognosis biomarkers in metastatic breast cancer through the prism of molecular profiling studies. The past decade was marked by several important studies deciphering the molecular landscape of metastatic breast cancer. Although the initial goal of these studies was to find driver oncogenic events to explain cancer progression and metastatic spreading, they have also permitted the identification of several molecular alterations associated with treatment response or resistance. Herein, we review validated (PI3KCA, ESR1, MSI, NTRK translocation) and emergent molecular biomarkers (ERBB2, AKT, PTEN, HRR gene, CD274 amplification RB1, NF1, mutational process) in metastatic breast cancer, on the bases of the largest molecular profiling studies. These biomarkers will be classed according the level of evidence and, if possible, the ESCAT (ESMO) classification. Finally, we will provide some perspective on development in clinical practice for the main biomarkers.

引用

页数：12

共 81 条

[51] Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group [J].

Mosele, F. ;

Remon, J. ;

Mateo, J. ;

Westphalen, C. B. ;

Barlesi, F. ;

Lolkema, M. P. ;

Normanno, N. ;

Scarpa, A. ;

Robson, M. ;

Meric-Bernstam, F. ;

Wagle, N. ;

Stenzinger, A. ;

Bonastre, J. ;

Bayle, A. ;

Michiels, S. ;

Bieche, I ;

Rouleau, E. ;

Jezdic, S. ;

Douillard, J-Y ;

Reis-Filho, J. S. ;

Dienstmann, R. ;

Andre, F. .

ANNALS OF ONCOLOGY, 2020, 31 (11) :1491-1505

[52] Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer [J].

Mosele, F. ;

Stefanovska, B. ;

Lusque, A. ;

Tran Dien, A. ;

Garberis, I ;

Droin, N. ;

Le Tourneau, C. ;

Sablin, M-P ;

Lacroix, L. ;

Enrico, D. ;

Miran, I ;

Jovelet, C. ;

Bieche, I ;

Soria, J-C ;

Bertucci, F. ;

Bonnefoi, H. ;

Campone, M. ;

Dalenc, F. ;

Bachelot, T. ;

Jacquet, A. ;

Jimenez, M. ;

Andre, F. .

ANNALS OF ONCOLOGY, 2020, 31 (03) :377-386

[53] Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies [J].

Nayar, Utthara ;

Cohen, Ofir ;

Kapstad, Christian ;

Cuoco, Michael S. ;

Waks, Adrienne G. ;

Wander, Seth A. ;

Painter, Corrie ;

Freeman, Samuel ;

Persky, Nicole S. ;

Marini, Lori ;

Helvie, Karla ;

Oliver, Nelly ;

Rozenblatt-Rosen, Orit ;

Ma, Cynthia X. ;

Regev, Aviv ;

Winer, Eric P. ;

Lin, Nancy U. ;

Wagle, Nikhil .

NATURE GENETICS, 2019, 51 (02) :207-+

[54] Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells [J].

Nikkilae, Jenni ;

Kumar, Rahul ;

Campbell, James ;

Brandsma, Inger ;

Pemberton, Helen N. ;

Wallberg, Fredrik ;

Nagy, Kinga ;

Scheer, Ildiko ;

Vertessy, Beata G. ;

Serebrenik, Artur A. ;

Monni, Valentina ;

Harris, Reuben S. ;

Pettitt, Stephen J. ;

Ashworth, Alan ;

Lord, Christopher J. .

BRITISH JOURNAL OF CANCER, 2017, 117 (01) :113-123

[55] The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial [J].

O'Leary, Ben ;

Cutts, Rosalind J. ;

Liu, Yuan ;

Hrebien, Sarah ;

Huang, Xin ;

Fenwick, Kerry ;

Andre, Fabrice ;

Loibl, Sibylle ;

Loi, Sherene ;

Garcia-Murillas, Isaac ;

Cristofanilli, Massimo ;

Bartlett, Cynthia Huang ;

Turner, Nicholas C. .

CANCER DISCOVERY, 2018, 8 (11) :1390-1403

[56] Drug therapy - Tamoxifen in the treatment of breast cancer [J].

Osborne, CK .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) :1609-1618

[57] Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers [J].

Palmeri, M. ;

Mehnert, J. ;

Silk, A. W. ;

Jabbour, S. K. ;

Ganesan, S. ;

Popli, P. ;

Riedlinger, G. ;

Stephenson, R. ;

de Meritens, A. B. ;

Leiser, A. ;

Mayer, T. ;

Chan, N. ;

Spencer, K. ;

Girda, E. ;

Malhotra, J. ;

Chan, T. ;

Subbiah, V ;

Groisberg, R. .

ESMO OPEN, 2022, 7 (01)

[58] RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD). [J].

Patsouris, Anne ;

Tredan, Olivier ;

Nenciu, Daniel ;

Tran-Dien, Alicia ;

Campion, Loic ;

Goncalves, Anthony ;

Arnedos, Monica ;

Sablin, Marie-Paule ;

Gouraud, Wilfried ;

Jimenez, Marta ;

Droin, Nathalie ;

Bieche, Ivan ;

Callens, Celine ;

Loehr, Andrea ;

Vicier, Cecile ;

Andre, Fabrice .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[59] PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer [J].

Rasti, Aryana R. ;

Guimaraes-Young, Amy ;

Datko, Farrah ;

Borges, Virginia F. ;

Aisner, Dara L. ;

Shagisultanova, Elena .

JCO PRECISION ONCOLOGY, 2022, 6

[60] The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers [J].

Razavi, Pedram ;

Chang, Matthew T. ;

Xu, Guotai ;

Bandlamudi, Chaitanya ;

Ross, Dara S. ;

Vasan, Neil ;

Cai, Yanyan ;

Bielski, Craig M. ;

Donoghue, Mark T. A. ;

Jonsson, Philip ;

Penson, Alexander ;

Shen, Ronglai ;

Pareja, Fresia ;

Kundra, Ritika ;

Middha, Sumit ;

Cheng, Michael L. ;

Zehir, Ahmet ;

Kandoth, Cyriac ;

Patel, Ruchi ;

Huberman, Kety ;

Smyth, Lillian M. ;

Jhaveri, Komal ;

Modi, Shanu ;

Traina, Tiffany A. ;

Dang, Chau ;

Zhang, Wen ;

Weigelt, Britta ;

Li, Bob T. ;

Ladanyi, Marc ;

Hyman, David M. ;

Schultz, Nikolaus ;

Robson, Mark E. ;

Hudis, Clifford ;

Brogi, Edi ;

Viale, Agnes ;

Norton, Larry ;

Dickler, Maura N. ;

Berger, Michael F. ;

Iacobuzio-Donahue, Christine A. ;

Chandarlapaty, Sarat ;

Scaltriti, Maurizio ;

Reis-Filho, Jorge S. ;

Solit, David B. ;

Taylor, Barry S. ;

Baselga, Jose .

CANCER CELL, 2018, 34 (03) :427-+

← 1 2 3 4 5 6 7 8 9 →